Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis

Published:2019-12-27 Issue:12 Volume:14 Page:e0226637
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

You Ching-Hui,Lin Cheng-Kuan,Chen Po-Hua,Park Suna,Chen Yi-Yun,Khan Nazleen,Papatheodorou Stefania I.,Chen Szu-Ta^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Outpatient antibiotic prescription data from QuintilesIMS (formerly IMS Health) Xponent data and U.S. Census files in an interactive database. https://giscdcgov/grasp/PSA/AUMapViewhtml. 2011.

2. Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin;M. Lebel;The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,1993

3. Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides;E Gorelik;Antimicrobial agents and chemotherapy,2018

4. Cardiovascular outcomes associated with use of clarithromycin: population based study;AY Wong;BMJ (Clinical research ed),2016

5. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and beta-lactam/beta-lactamase inhibitors: a Taiwanese nationwide study;HW Chou;Clin Infect Dis,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac events after using clarithromycin for anti-Helicobacter pylori therapy in patients with coronary artery disease;Medicine;2023-11-10

2. Administration of macrolide antibiotics increases cardiovascular risk;Frontiers in Cardiovascular Medicine;2023-02-23

3. Triggering of cardiovascular disease by infection type: The Atherosclerosis Risk in Communities study (ARIC);International Journal of Cardiology;2021-02